rofecoxib has been researched along with Urticaria in 16 studies
Urticaria: A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To classify patients with a history of aspirin-induced urticaria as cross-reactors or single-drug reactors by oral challenges with another strong COX-1 inhibitor, namely, ketoprofen." | 9.12 | Use of ketoprofen oral challenges to detect cross-reactors among patients with a history of aspirin-induced urticaria. ( Asero, R, 2006) |
| "To classify patients with a history of aspirin-induced urticaria as cross-reactors or single-drug reactors by oral challenges with another strong COX-1 inhibitor, namely, ketoprofen." | 5.12 | Use of ketoprofen oral challenges to detect cross-reactors among patients with a history of aspirin-induced urticaria. ( Asero, R, 2006) |
| " Three subjects with multiple-drug induced urticaria complained of a generalized reaction after challenge (Two due to celecoxib and one due to meloxicam)." | 5.11 | Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. ( Antonicelli, L; Bilò, MB; Bonadonna, P; Crivellaro, MA; Dama, AR; Schiappoli, M; Senna, G, 2004) |
| "To compare the clinical tolerance to rofecoxib and valdecoxib in patients who previously developed urticaria and angioedema while taking classic NSAIDs." | 5.11 | Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib. ( Caballero-Fonseca, F; Capriles-Hulett, A; Sánchez-Borges, M, 2005) |
| "Evaluate aspirin challenge as a means to distinguish single from multiple NSAID intolerance in patients with a clinical history of acute urticaria induced by a single NSAID." | 5.11 | Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs. ( Asero, R, 2005) |
| "Rofecoxib appears to be a safe alternative drug among atopic individuals, antibiotic-hypersensitive individuals, and individuals who experienced adverse cutaneous reactions to more than 1 class of NSAIDs, but it is less safe among chronic urticaria patients." | 3.73 | Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs. ( Colanardi, MC; Ferrannini, A; Nettis, E; Tursi, A, 2005) |
| " One hundred twenty-seven subjects with history of adverse reaction to ASA/NSAIDs received oral challenges with nimesulide, 61 subjects were challenged with meloxicam, 51 subjects were challenged with rofecoxib, and 37 subjects were challenged with all three drugs." | 2.71 | Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib. ( Bavbek, S; Celik, G; Misirligil, Z; Mungan, D; Ozer, F, 2004) |
| "Rofecoxib is a safe alternative in subjects with previous adverse cutaneous reaction to NSAIDs." | 2.70 | Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs. ( Barbagallo, M; Biasi, D; Corrocher, R; Di Lorenzo, G; Pacor, ML, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Valero, A | 1 |
| Baltasar, M | 1 |
| Enrique, E | 2 |
| Pau, L | 1 |
| Dordal, MT | 1 |
| Cisteró, A | 1 |
| Martí, E | 1 |
| Picado, C | 1 |
| Boehncke, WH | 1 |
| Ludwig, RJ | 1 |
| Zollner, TM | 1 |
| Ochsendorf, F | 1 |
| Kaufmann, R | 1 |
| Gibbs, BF | 1 |
| Zembowicz, A | 1 |
| Mastalerz, L | 1 |
| Setkowicz, M | 1 |
| Radziszewski, W | 1 |
| Szczeklik, A | 1 |
| Rodríguez, M | 1 |
| Castello, JV | 1 |
| de Mateo, JA | 1 |
| Roca, B | 1 |
| Malek, T | 1 |
| Bavbek, S | 1 |
| Celik, G | 1 |
| Ozer, F | 1 |
| Mungan, D | 1 |
| Misirligil, Z | 1 |
| Senna, G | 1 |
| Bilò, MB | 1 |
| Antonicelli, L | 1 |
| Schiappoli, M | 1 |
| Crivellaro, MA | 1 |
| Bonadonna, P | 1 |
| Dama, AR | 1 |
| Nettis, E | 1 |
| Colanardi, MC | 1 |
| Ferrannini, A | 1 |
| Tursi, A | 1 |
| Sánchez-Borges, M | 1 |
| Caballero-Fonseca, F | 1 |
| Capriles-Hulett, A | 1 |
| Asero, R | 3 |
| Hirschfeld, G | 1 |
| Sperfeld, AD | 1 |
| Kassubek, J | 1 |
| Scharffetter-Kochanek, K | 1 |
| Sunderkötter, C | 1 |
| Kelkar, PS | 1 |
| Butterfield, JH | 1 |
| Teaford, HG | 1 |
| Grimm, V | 1 |
| Rakoski, J | 1 |
| Ring, J | 1 |
| Pacor, ML | 1 |
| Di Lorenzo, G | 1 |
| Biasi, D | 1 |
| Barbagallo, M | 1 |
| Corrocher, R | 1 |
8 trials available for rofecoxib and Urticaria
| Article | Year |
|---|---|
Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy; Celecoxib; Comput | 2003 |
Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cyclooxygenase In | 2004 |
Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
Topics: Adolescent; Adult; Aged; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Celec | 2004 |
Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Child; Cyclooxygenase Inhibitors | 2005 |
Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anal | 2005 |
Use of ketoprofen oral challenges to detect cross-reactors among patients with a history of aspirin-induced urticaria.
Topics: Acetaminophen; Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroida | 2006 |
Urticaria and angioedema induced by COX-2 inhibitors.
Topics: Angioedema; Controlled Clinical Trials as Topic; Cyclooxygenase Inhibitors; Double-Blind Method; Fem | 2002 |
Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Double-Blind Met | 2002 |
8 other studies available for rofecoxib and Urticaria
| Article | Year |
|---|---|
NSAID-sensitive patients tolerate rofecoxib.
Topics: Adolescent; Adult; Aged; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Controlled Cli | 2002 |
The selective cyclooxygenase-2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Cyclooxygenase Inhibitors; Female; | 2003 |
Tolerability of cyclooxygenase 2 inhibitors and the advisability of oral challenge.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; | 2003 |
[Minor rate of side-effects makes it possible. Coxibs accrue new indications].
Topics: Analgesics; Anti-Inflammatory Agents; Cyclooxygenase Inhibitors; Drug Interactions; Humans; Lactones | 2004 |
Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Cyclooxygenase Inhibitors; Drug Hypers | 2005 |
[Transient global amnesia (TGA) during an oral provocation test].
Topics: Administration, Oral; Amnesia, Transient Global; Anti-Inflammatory Agents, Non-Steroidal; Blood Pres | 2007 |
Tolerability of rofecoxib.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Drug Tolerance; Fem | 2001 |
Urticaria and angioedema from cyclooxygenase-2 inhibitors.
Topics: Adult; Aged; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibito | 2001 |